\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Hormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2016-01-15 (revised: 15 January 2016)} \def\TheID{\makeatother } \def\TheDate{2016-01-15} \title{Hormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Awad Magbri} \affil[1]{ Dialysis Access Center of Pittsburgh} \renewcommand\Authands{ and } \date{\small \em Received: 15 December 2015 Accepted: 2 January 2016 Published: 15 January 2016} \maketitle \begin{abstract} This study evaluates divalent ion abnormalities (DIA) and the hormonal changes throughout the spectrum of early CKD stages (1-4) as defined by K/DOQI. A total of 96 patients (48.96% males, mean age 62±13 yrs) with CKD 1 to 4, were prospectively evaluated and followed-up. There were (20, 27, 32, and 17 patients in CKD-1, 2, 3, and 4 respectively). The diagnosis was confirmed by renal biopsy, Table- 1.Mean serum creatinine (62±32 umol/L). Plasma levels of calcium, phosphorus, calcitriol (CTRL), and parathyroid hormone (PTH) were evaluated among the groups. A 24-hour urinary creatinine, calcium (Uca), phosphorus (Up), creatinine clearance and fractional excretion of calcium (FeCa), and phosphorus (FeP) were also compared. PTH was measured using the standard IRMA test (normal values 10-50 pg/dl), and calcitriol was measured by RIA test (normal values are 74.5 â??" 169 pmol/l). The exclusion criteria are nephrolithiasis, hypercalcemia, proteinuria >3g/24 hrs, previous renal transplant, and therapy with steroids or anticonvulsants (Phenytoin). \end{abstract} \keywords{divalent ion abnormality, CKD, calcitriol, secondary hyperparathyroidism, hyperphosphatemia, hypocalcemia, parathyroid hormone (PTH).} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Hormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases}]{Hormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases}\par Awad Magbri ? , Hervas JG ? , Eussera El-Magbri ? , Mariam El-Magbri ? , Taha El-Magbri ¥ \& Llach F § Abstract-This study evaluates divalent ion abnormalities (DIA) and the hormonal changes throughout the spectrum of early CKD stages \hyperref[b0]{(1)}\hyperref[b1]{(2)}\hyperref[b2]{(3)}\hyperref[b3]{(4)} as defined by K/DOQI. A total of 96 patients (48.96\% males, mean age 62±13 yrs) with CKD 1 to 4, were prospectively evaluated and followed-up. There were \hyperref[b19]{(20,}\hyperref[b26]{27,}\hyperref[b31]{32}, and 17 patients in CKD-1, 2, 3, and 4 respectively). The diagnosis was confirmed by renal biopsy, Table {\ref -}1.Mean serum creatinine (62±32 umol/L). Plasma levels of calcium, phosphorus, calcitriol (CTRL), and parathyroid hormone (PTH) were evaluated among the groups. A 24-hour urinary creatinine, calcium (Uca), phosphorus (Up), creatinine clearance and fractional excretion of calcium (FeCa), and phosphorus (FeP) were also compared. PTH was measured using the standard IRMA test (normal values 10-50 pg/dl), and calcitriol was measured by RIA test (normal values are 74.5 -169 pmol/l). The exclusion criteria are nephrolithiasis, hypercalcemia, proteinuria >3g/24 hrs, previous renal transplant, and therapy with steroids or anticonvulsants (Phenytoin).\par The serum Ca levels were not different among the four groups (Fig- {\ref 1}), however, urinary calcium decreased progressively from 207±11 (CKD-1) to 56±44 (CKD-4, P<0.01), (Fig- {\ref 2}).The urinary calcium excretion was directly correlated with CTRL; and inversely correlated with PTH, (p<0.001 and p<0.01, respectively), (Fig- {\ref 3}).Even though, serum phosphorus increased only in CKD-4 (p<0.01), (Fig- {\ref 4}), it was significantly correlated with the overall decrement of GFR (p<0.0001), (Fig- {\ref 5}). Likewise, the overall decrement in GFR was correlated with UP (p<0.0001), (Fig- {\ref 6}).Serum phosphorus has a positive linear correlation with CTRL and inversely correlated with PTH levels (p<0.0001, and p<0.001), respectively, (Fig- {\ref 7}, and Table -2).The Ca x P product was also positively correlated with PTH and negatively with CTRL, (p<0.001 and p<0.001, respectively), (Fig- {\ref 8}).As expected, there was a positive increase in PTH levels with increased CKD stage, this was significant in CKD-3 (p<0.001), (Fig- {\ref 9}).There was a significant correlation between GFR and PTH levels (p<0.0001), (Fig- {\ref 10}).Finally, CTRL levels decreased in CKD-3 (p<0.001), (Fig- {\ref 11}, Fig- {\ref 12 and Table-3}), and were overall, correlated with the decrement in GFR (p<0.0001).\par Conclusion: A significant positive calcium and phosphate balance together with a deficit of CTRL develop early in CKD patients. Secondary hyperparathyroidism with divalent ion and CTRL abnormalities are important events in CKD patients I. Introduction hronic kidney disease afflicts between 2.5 and 18 million Americans with millions more at increased risk for the disorder \hyperref[b0]{(Jones 1998} {\ref , NKF 2002)}. The national kidney foundation (K/DOQI) classified kidney disease into 5 stages based on the estimated glomerular filtration rate (eGFR) before patients go on dialysis or for transplantation. As the GFR declines, the incidence of co-morbid conditions such as hypertension, anemia, left ventricular hypertrophy, mineral and bone disorders (CKD-MBD) increase.\par Disturbances of bone and mineral metabolism are common in CKD. Increase in serum phosphate and decrease in 1, 25-dihydroxyvitamin D3 occur early in the course of the disease (GFR<60 ml/min/1.73m²), whereas hypocalcemia is a relatively late finding (GFR<20 mL/min/1.73 m²).\par The pathophysiology of CKD-MBD involves many feedback loops between the intestine, the kidney, and the vasculature to maintain calcium and phosphorus balance. While most elements of CKD-MBD are usually present when the glomerular filtration rate (GFR) falls below 40 mL/min, some components may be observed earlier in the course of CKD and precede the onset of clinically detectable abnormalities in serum phosphorus, calcium, PTH, and vitamin D (Fang 2014, Pereira 2009, Sabbagh 2012, Oliveira 2010, Isakova 2011). \section[{II. Subjects and Methods}]{II. Subjects and Methods}\par This study evaluates divalent ion abnormalities (DIA) and the hormonal changes throughout the spectrum of early CKD stages (1-4) as defined by K/DOQI. A total of 96 patients (48.96\% males, mean age 62±13 yrs) with CKD 1 to 4, were prospectively evaluated and followed-up. There were \hyperref[b19]{(20,}\hyperref[b26]{27,}\hyperref[b31]{32}, and 17 patients in CKD-1, 2, 3, and 4 respectively). The diagnosis was confirmed by renal biopsy, Table-1.\par Mean serum creatinine (62±32 umol/L). Plasma levels of calcium, phosphorus, calcitriol (CTRL), and parathyroid hormone (PTH) were evaluated among the groups.\par A 24-hour urinary creatinine, calcium (Uca), phosphorus (Up), creatinine clearance and fractional excretion of calcium (FeCa), and phosphorus (FeP) were also compared.\par PTH was measured using the standard IRMA test (normal values 10-50 pg/dl), and calcitriol was measured by RIA test (normal values are 74.5 -169 pmol/l)\par The exclusion criteria are nephrolithiasis, hypercalcemia, proteinuria >3g/24 hrs, previous renal transplant, and therapy with steroids or anticonvulsants (Phenytoin). \section[{a) Statistical analysis}]{a) Statistical analysis}\par SPSS software version 9.0 was used to analysis the data. ANOVA or analysis of variance was used to compare group means when applicable. \section[{III. Results}]{III. Results}\par The serum Ca levels were not different among the four groups (Fig- {\ref 1}), however, urinary calcium decreased progressively from 207±11 (CKD-1) to 56±44 (CKD-4, P<0.01), (Fig- {\ref 2}).\par The urinary calcium excretion was directly correlated with CTRL; and inversely correlated with PTH, (p<0.001 and p<0.01, respectively), (Fig- {\ref 3}).\par Even though, serum phosphorus increased only in CKD-4 (p<0.01), (Fig- {\ref 4}), it was significantly correlated with the overall decrement of GFR (p<0.0001), (Fig- {\ref 5}).\par Likewise, the overall decrement in GFR was correlated with UP (p<0.0001), (Fig- {\ref 6}).\par Serum phosphorus has a positive linear correlation with CTRL and inversely correlated with PTH levels (p<0.0001, and p<0.001), respectively, (Fig- {\ref 7}, and Table -2).\par The Ca x P product was also positively correlated with PTH and negatively with CTRL, (p<0.001 and p<0.001, respectively), (Fig- {\ref 8}).\par As expected, there was a positive increase in PTH levels with increased CKD stage, this was significant in CKD-3 (p<0.001), (Fig- {\ref 9}).\par There was a significant correlation between GFR and PTH levels (p<0.0001), (Fig- {\ref 10}).\par Finally, CTRL levels decreased in CKD-3 (p<0.001), (Fig- {\ref 11}, Fig- {\ref 12} and Table-3), and were overall, correlated with the decrement in GFR (p<0.0001). \section[{IV. Discussion}]{IV. Discussion}\par Phosphate retention and secondary hyperparathyroidism (SHPT) are the main biochemical abnormalities in CKD-MBD. Secondary hyperparathyroidism begins early in the course of CKD as clearly demonstrated in this study, and the prevalence increases as kidney function declines (particularly to estimated glomerular filtration rate [eGFR] <60 mL/min/ 1.73 m 2 ). Secondary hyperparathyroidism occurs in response to a series of abnormalities that initiate and maintain increased PTH secretion \hyperref[b8]{(Cunningham 2011}). The main abnormalities that contribute to the pathogenesis of SHPT are; i-phosphate retention, iidecreased free ionized calcium concentration, iiidecreased 1,25-dihydroxyvitamin D (CTRL) concentration, vi-increased fibroblast growth factor 23 (FGF-23) concentration, v-the reduced vitamin receptor expression and calcium sensing receptors in the parathyroid gland.\par The increased PTH concentrations becomes evident when the eGFR drops <60 mL/min/1.73 m 2 , CKD-3 At that time, serum calcium and phosphate concentrations are normal and remain within normal ranges until the eGFR decreases to approximately 20 mL/min/ 1.73 m 2 \hyperref[b9]{(Levin 2007)}. Circulating CTRL concentrations begin to fall much earlier, when the GFR is <60 mL/min per 1.73 m 2 (Levin 2007), CKD-3, Fig- {\ref 12}, and are markedly reduced in patients with end-stage renal disease (ESRD) \hyperref[b10]{(Pitts 1988}). The primary reason for the decline in CTRL concentration is likely an increase in FGF-23 concentration. Even though, FGF-23 was not measured in this study but its role has been demonstrated in other studies \hyperref[b7]{(Gutierrez 2005)}. Reduced functioning nephrons and hyperphosphatemia are accessory factors for the decline in CTRL \hyperref[b7]{(Gutierrez 2005)}. Hyperphosphatemia is a relatively late phenomenon (CKD-4) and may also contribute to the decline in CTRL synthesis by suppression of 1-alphahydroxylase enzyme, Fig- {\ref 4}.\par Phosphate retention has long been thought to be the initial trigger for many of the components of CKD-MBD, particularly the increased PTH secretion. A tendency to phosphate retention, beginning early in CKD as the decline in GFR decreases the filtered phosphate load, is thought to play a central role in the development of secondary hyperparathyroidism \hyperref[b11]{(Martin 2007} {\ref , NKF 2002}\hyperref[b12]{, Kates 1997}). This could not besupported by this study, Fig- {\ref 4}. Hypocalcemia, decreased activity of CTRL, and increased PTH gene expression have been proposed to explain how phosphate retention initially promotes PTH release \hyperref[b13]{(Hruska 1995}\hyperref[b14]{, Fournier 1992}\hyperref[b15]{, Liach 1995)}.\par If phosphate is reduced by restricting phosphate intake in proportion to the reduction in GFR, or the use of phosphate binders in established hyperphosphatemia, these measures could prevent the rise in plasma PTH concentration,partially reverse the hypocalcemia, hyperparathyroidism, and CTRL deficiency \hyperref[b15]{(Liach 1995)}.\par The secondary hyperparathyroidism is maladaptive over the long-term \hyperref[b15]{(Liach 1995)}, and the effect of PTH on phosphate balance changes as GFR declines. Since phosphate reabsorption by the renal tubules cannot be lowered below a minimum threshold, Plasma CTRL concentrations generally fall below normal when the GFR is <60 mL/min per 1.73 m 2 , (CKD-3), Fig- {\ref 12}. Low concentrations of CTRL have also been found in some patients with higher eGFR (ie, <80 mL/min per 1.73 m 2 ) \hyperref[b9]{(Levin 2007}\hyperref[b15]{, Liach 1995}\hyperref[b19]{, Koenig 1992}\hyperref[b20]{, Wilson 1985}\hyperref[b21]{, Gutierrez 2008)}. \section[{Volume Issue II Version I}]{Volume Issue II Version I}\par The decline in CTRL is first due to increased FGF-23 followed later by reduced functioning renal mass, when GFR drops to <70 ml/min/1.73m2. In advance CKD, hyperphosphatemia may play a significant role \hyperref[b7]{(Gutierrez 2005)}. The hyperphosphatemia and low CTRL will have direct and indirect effect on PTH concentration. The indirect effect is achieved via decreased intestinal absorption of calcium as well as release of calcium from bone These effects propagate hypocalcemia which stimulate PTH secretion \hyperref[b22]{(Hsu 1994}\hyperref[b23]{, Silver 1986}\hyperref[b24]{, Malluche 2002)}.\par Through vitamin D receptors, CTRL suppress PTH transcription by the parathyroid gland {\ref (Brumbaugh 1975)}. By time, the VDRs concentration in the parathyroid gland decrease and along with low levels of CTRL will promote parathyroid cell hyperplasia and nodular hyperparathyroidism \hyperref[b26]{(Denda 1996}.\par More importantly, low CTRL concentration can increase PTH secretion by removing the inhibitory effect of CTRL on the parathyroid gland \hyperref[b15]{(Liach 1995}\hyperref[b27]{, Slatopolsky 1984)}, Table-3. The administration of CTRL, on the other hand, can partially reverse SHPT both in early \hyperref[b20]{(Wilson 1985)} and advanced kidney disease \hyperref[b27]{(Slatopolsky 1984)}.\par There is also evidence that decreased responsiveness to CTRL contributes to the development of hyperparathyroidism. In particular, physiologic concentrations of CTRL may be unable to normally suppress PTH secretion, perhaps due to a reduction in the number of VDRs in the parathyroid gland \hyperref[b26]{(Denda 1996}\hyperref[b28]{, Fukuda 1993)}. Studies in patients on maintenance dialysis reveal that the decrease in receptor density is most prominent in areas of nodular, rather than diffuse, hyperplasia \hyperref[b28]{(Fukuda 1993)}.\par Therefore, a reduced number of VDRs may contribute both to the progression of SHPT and to the proliferation of parathyroid cells, leading to nodular hyperplasia.\par Minute changes in ionized calcium are sensed by the CaSRs in the parathyroid gland which regulate PTH secretion \hyperref[b29]{(Rodriguez 2005)}. The fall in serum calcium concentration in CKD, as sensed by the CaSR, is a potent stimulus to the release of PTH \hyperref[b30]{(Li 1998}\hyperref[b31]{, Panda 2004}). Decreased CTRL levels, hyperphosphatemia, and PTH resistance on the bone cause the hypocalcemia of SHP in advanced CKD.. This could not be demonstrated in this study, as the level of total calcium is almost normal in all the stages of CKD \hyperref[b0]{(1)}\hyperref[b1]{(2)}\hyperref[b2]{(3)}\hyperref[b3]{(4)}. This apparent controversy could be explained by low ionized calcium level even in the face of normal total calcium level. PTH secretion varies inversely with serum calcium concentration \hyperref[b16]{(Silver 2005)}. Persistently low serum calcium concentrations also appear to directly increase PTH mRNA concentrations via posttranscriptional actions and stimulate the proliferation of parathyroid cells over days or weeks {\ref (Silver 2005, Wilson1985)}.\par The shortcoming of this study is the small sample size of patients studied and the fact that it has been carried out in one center which may not be applied widely on different ethnic groups. The measurement of CTRL, PTH, and serum calcium and phosphate are done on snap shot which may not be representative of their dynamic state in living individuals. \section[{V. Conclusion}]{V. Conclusion}\begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-2.png} \caption{\label{fig_0}}\end{figure} \footnote{© 2016 Global Journals Inc. (US)} \backmatter \begin{bibitemlist}{1} \bibitem[Denda et al. ()]{b26}\label{b26} ‘1,25-dihydroxyvitamin D3 and 22-oxacacitriol revent the decrease in vitamin D receptor content in parathyroid glands of uremic rats’. M Denda , J Finch , A J Brown . \textit{Kidney Int} 1996. 50 p. 34. \bibitem[Wilson et al. ()]{b20}\label{b20} ‘Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D’. L Wilson , A Felsenfeld , M K Drezner , F Liach . \textit{Kidney Int} 1985. 27 p. 565. \bibitem[Silver and Levi ()]{b16}\label{b16} ‘Cellular and molecular mechanisms of secondary hyperparathyroidism’. J Silver , R Levi . \textit{Clin Nephrol} 2005. 63 p. 119. \bibitem[Saito et al. ()]{b18}\label{b18} ‘Circulating FGF-23 is regulated by 1 alpha, 25 dihydroxyvitamin D3 and phosphorus in vivo’. H Saito , A Maeda , S Ohtomo . \textit{J Biol Chem} 2005. 280 p. 2543. \bibitem[Brumbaugh et al.]{b25}\label{b25} ‘Cytoplasmic and nuclear binding components for 1-alpha 25-dihydroxyvitamin D3 in chick parathyroid glands’. P F Brumbaugh , M R Hughes , M R Haussler . 1975: 72: 4871. \textit{Proc Natl Acad Sci} \bibitem[Fukuda et al. ()]{b28}\label{b28} ‘Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients’. N Fukuda , H Tanaka , Y Tominaga . \textit{J Clin Invest} 1993. 92 p. 1436. \bibitem[Fang et al. ()]{b2}\label{b2} ‘Early chronic kidney disease-mineral bone disorder stimulates vascular calcification’. Y Fang , C Ginsberg , T Sugatani . \textit{Kidney Int} 2014. p. 142. \bibitem[Oliveira et al. ()]{b5}\label{b5} ‘Early control of PTH and FGF-23 in nonmorphosphatemic CKD patients a new target in CKD-MBD therapy?’. R B Oliveira , A L Cancela , F G Graciolli . \textit{Cli J AM SocNephrol} 2010. 5 p. 286. \bibitem[Wetmore et al. ()]{b17}\label{b17} ‘Effects of cinacalcet and concurrent low dose vitamin D on FGF23 levels in ESRD’. J B Wetmore , S Liu , R Krebill . \textit{Clin J AM Nephrol} 2010. 5 p. 110. \bibitem[Kates et al. ()]{b12}\label{b12} ‘Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure’. D M Kates , D J Sherrard , D L Andress . \textit{AM J Kidney Dis} 1997. 30 p. 809. \bibitem[Isakova et al. ()]{b6}\label{b6} ‘Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disase’. T Isakova , P Wahl , G S Vargas . \textit{Kidney Int} 2011. 79 p. 1370. \bibitem[Gutierrez et al. ()]{b7}\label{b7} ‘Fibroblast growth factor-23 mitigate hyperphosphatemia but accentuate calcitriol deficiency in chronic kidney disease’. O Gutierrez , T Isakova , E Rhee . \textit{J AM SocNephrol} 2005. 16 p. 2205. \bibitem[Koenig et al. ()]{b19}\label{b19} ‘Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease’. K G Koenig , J S Lindberg , J E Zerwekh . \textit{Kidney Int} 1992. 41 p. 161. \bibitem[Pitts et al. ()]{b10}\label{b10} ‘Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure’. T O Pitts , B H Piraino , R Mitro . \textit{J Clin Endocrinol Metabolism} 1988. 67 p. 876. \bibitem[Panda et al. ()]{b31}\label{b31} ‘Inactivation of the 25-hydroxyvitamin D 1-alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis’. D K Panda , D Miao , I Bolivar . \textit{J BiolChem} 2004. p. 16754. \bibitem[Kidney Disease Outcome Quality Initiative (K/DOQI), Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification Am J Kidney Dise ()]{b1}\label{b1} ‘Kidney Disease Outcome Quality Initiative (K/DOQI), Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification’. \textit{Am J Kidney Dise} 2002. 39 (2) . National Kidney Foundation (NKF) (Suppl 2) S-249) \bibitem[Slatopolsky et al. ()]{b27}\label{b27} ‘Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients’. E Slatopolsky , C Weerts , J Thielan . \textit{J ClinInvest} 1984. 74 p. 2136. \bibitem[Martin and Gonzalez ()]{b11}\label{b11} ‘Metabolic bone disease in chronic kidney disease’. K J Martin , E A Gonzalez . \textit{J AM Soc Nephrol} 2007. 18 p. 875. \bibitem[Li et al. ()]{b30}\label{b30} ‘Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice’. Y C Li , M Amling , A E Pirro . \textit{Endocrinology} 1998. 139 p. 4391. \bibitem[Gutierrez et al. ()]{b21}\label{b21} ‘Prevalence and severity of disordered mineral metabolism in blacks with chronic kidney disease’. O M Gutierrez , T Isakova , D L Andress . \textit{Kidney Int} 2008. p. 956. \bibitem[Levin et al. ()]{b9}\label{b9} ‘Prevelance of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease’. A Levin , G L Bakris , M Molitch . \textit{KidenyInt} 2007. 71 p. 31. \bibitem[Pereira et al. ()]{b3}\label{b3} \textit{Pttren of FGF-23, DMPI, and MEPE expression in patients with chronic kidney disease Bone}, R C Pereira , H Juppner , Azucena - Serrano , CE . 2009. 45 p. 1161. \bibitem[Silver et al. ()]{b23}\label{b23} ‘Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat’. J Silver , T Naveh-Many , H Mayer . \textit{J Clin Invest} 1986. 78 p. 1296. \bibitem[Hruska and Teitelbaum ()]{b13}\label{b13} ‘Renal osteodystrophy’. K A Hruska , S L Teitelbaum . \textit{N Engl J Med} 1995. 333 p. 166. \bibitem[Sabbagh et al. ()]{b4}\label{b4} ‘Repression of osteocyte Wnt/B-catenin signaling is as early event in the progression of renal osteodystrophy’. Y Sabbagh , F G Graciolli , S O'brien . \textit{J Bone Miner Res} 2012. 27 p. 175. \bibitem[Liach ()]{b15}\label{b15} ‘Secondary hyperparathyroidism in renal failure; The trade-off hypothesis revisited’. F Liach . \textit{Am J Kidney Disease} 1995. 25 p. 663. \bibitem[Cunningham et al. ()]{b8}\label{b8} ‘Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options’. J Cunningham , F Locatelli , M Rodriguez . \textit{Cli J AM SocNephrol} 2011. 6 p. 913. \bibitem[Jones et al. ()]{b0}\label{b0} ‘Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey’. C A Jones , G M Mcquillan , J W Kusek . \textit{Am J Kidney Dis} 1998. 32 p. . \bibitem[Hsu et al. ()]{b22}\label{b22} ‘The biological action of calcitriol in renal failure’. C H Hsu , S R Patel , E W Young , R Vanholder . \textit{Kidney Int} 1994. 46 p. 605. \bibitem[Rodriguez et al. ()]{b29}\label{b29} ‘The calciumsensing receptor: a key in the pathogenesis of secondary hyperparathyroidism’. M Rodriguez , E Nemeth , D Martin . 288: F253. \textit{Am J Physiol Renal Physiol} 2005. \bibitem[Malluche et al. ()]{b24}\label{b24} ‘Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure’. H H Malluche , H Mawad , N J Koszewski . \textit{Kidney Int} 2002. 62 p. 367. \bibitem[Fournier et al. ()]{b14}\label{b14} ‘Use of alkaline calcium salts as phosphate binder in uremic patients’. A Fournier , P Moriniere , Ben Hamida , F . \textit{Kidney IntSuppl} 1992. 38 p. S50. \end{bibitemlist} \end{document}